Eyenovia Regains Compliance with All Nasdaq Continued Listing Requirements
Eyenovia (NASDAQ: EYEN) has successfully regained compliance with all Nasdaq Capital Market continued listing requirements, including the minimum bid price requirement rule (Rule 5550(a)(2)) and the low priced stocks rule (Rule 5810(c)(3)(A)(iii)). The compliance was achieved following a recently approved reverse stock split.
CEO Michael Rowe emphasized that maintaining the Nasdaq listing, combined with company restructuring efforts and accelerated development of the user-filled Optejet® device, represents significant milestones as they continue to explore strategic alternatives to maximize shareholder value.
Eyenovia (NASDAQ: EYEN) ha riacquistato con successo la conformità a tutti i requisiti di quotazione continua del Nasdaq Capital Market, inclusi il requisito del prezzo minimo delle azioni (Regola 5550(a)(2)) e la regola delle azioni a basso prezzo (Regola 5810(c)(3)(A)(iii)). La conformità è stata raggiunta dopo un recente frazionamento azionario inverso approvato.
Il CEO Michael Rowe ha sottolineato che mantenere la quotazione al Nasdaq, insieme agli sforzi di ristrutturazione dell'azienda e allo sviluppo accelerato del dispositivo Optejet® riempito dall'utente, rappresenta traguardi significativi mentre continuano a esplorare alternative strategiche per massimizzare il valore per gli azionisti.
Eyenovia (NASDAQ: EYEN) ha recuperado con éxito el cumplimiento de todos los requisitos de cotización continua del Nasdaq Capital Market, incluidos el requisito del precio mínimo de oferta (Regla 5550(a)(2)) y la regla de acciones de bajo precio (Regla 5810(c)(3)(A)(iii)). El cumplimiento se logró tras una reciente división inversa de acciones aprobada.
El CEO Michael Rowe enfatizó que mantener la cotización en Nasdaq, combinado con los esfuerzos de reestructuración de la empresa y el desarrollo acelerado del dispositivo Optejet® llenado por el usuario, representa hitos significativos mientras continúan explorando alternativas estratégicas para maximizar el valor para los accionistas.
아이노비아 (NASDAQ: EYEN)는 최소 입찰 가격 요건 규칙(규칙 5550(a)(2)) 및 저가 주식 규칙(규칙 5810(c)(3)(A)(iii))을 포함한 모든 나스닥 자본 시장 지속 상장 요건을 성공적으로 회복했습니다. 이는 최근 승인된 주식 분할을 통해 달성되었습니다.
CEO 마이클 로우는 나스닥 상장 유지를 강조하며, 회사 재구성 노력과 사용자 채워진 Optejet® 장치의 가속 개발이 주주 가치를 극대화하기 위한 전략적 대안을 계속 탐색하는 과정에서 중요한 이정표가 된다고 말했습니다.
Eyenovia (NASDAQ: EYEN) a réussi à retrouver la conformité avec tous les critères de cotation continue du Nasdaq Capital Market, y compris la règle du prix de soumission minimum (Règle 5550(a)(2)) et la règle des actions à bas prix (Règle 5810(c)(3)(A)(iii)). La conformité a été atteinte suite à une récente division d'actions inversée approuvée.
Le PDG Michael Rowe a souligné que le maintien de la cotation sur le Nasdaq, combiné aux efforts de restructuration de l'entreprise et au développement accéléré du dispositif Optejet® rempli par l'utilisateur, représente des jalons significatifs alors qu'ils continuent d'explorer des alternatives stratégiques pour maximiser la valeur pour les actionnaires.
Eyenovia (NASDAQ: EYEN) hat erfolgreich die Einhaltung aller Anforderungen für die fortlaufende Listung am Nasdaq Capital Market wiederhergestellt, einschließlich der Mindestgebotsanforderung (Regel 5550(a)(2)) und der Regel für niedrigpreisige Aktien (Regel 5810(c)(3)(A)(iii)). Die Einhaltung wurde nach einer kürzlich genehmigten Aktienzusammenlegung erreicht.
CEO Michael Rowe betonte, dass die Aufrechterhaltung der Nasdaq-Listung, kombiniert mit den Umstrukturierungsbemühungen des Unternehmens und der beschleunigten Entwicklung des vom Benutzer gefüllten Geräts Optejet®, bedeutende Meilensteine darstellt, während sie weiterhin strategische Alternativen zur Maximierung des Shareholder-Values erkunden.
- Regained full Nasdaq listing compliance
- Avoided potential delisting risk
- Successfully implemented reverse stock split
- Required reverse stock split to maintain listing
- Company under restructuring
- Still evaluating strategic alternatives indicating uncertainty
NEW YORK, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN) (“Eyenovia” or the “Company"), an ophthalmic technology company focused on completing development of its proprietary Optejet® device, today announced that it has been informed by staff of The Nasdaq Stock Market LLC that the Company has regained compliance with all Nasdaq Capital Market continued listing requirements, including Nasdaq Listing Rule 5550(a)(2), the minimum bid price requirement rule, and Listing Rule 5810(c)(3)(A)(iii), the low priced stocks rule.
“Maintaining our Nasdaq listing, along with other steps we have taken to restructure the company and accelerate development of the user-filled Optejet, represent important milestones as we continue to evaluate a broad range of strategic alternatives and maximize shareholder value,” stated Michael Rowe, Chief Executive Officer. “We are grateful to our shareholders who approved of our recent decision to effect a reverse stock split that made it possible for us to regain compliance with the Nasdaq continued listing requirements.”
About Eyenovia, Inc.
Eyenovia, Inc. is an ophthalmic technology company developing its proprietary Optejet topical ophthalmic medication dispensing platform. The Optejet is especially useful in chronic front-of-the-eye diseases due to its ease of use, enhanced safety and tolerability, and potential for superior compliance versus standard eye drops. Together, these benefits may combine to produce better treatment options and outcomes for patients and providers. For more information, please visit Eyenovia.com.
Forward Looking Statements
Except for historical information, all the statements, expectations and assumptions contained in this press release are forward-looking statements. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions or any other statements relating to our future activities or other future events or conditions, including those relating to the estimated market opportunities for our platform technology, the timing for sales growth of our approved products, and the outcome of the process to explore strategic alternatives to maximize shareholder value. These statements are based on current expectations, estimates and projections about our business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may, and in some cases are likely to, differ materially from what is expressed or forecasted in the forward-looking statements due to numerous factors discussed from time to time in documents which we file with the U.S. Securities and Exchange Commission.
In addition, such statements could be affected by risks and uncertainties related to, among other things: risks of our clinical trials, including, but not limited to, the potential advantages of our products, and platform technology; the rate and degree of market acceptance and clinical utility of our products; our estimates regarding the potential market opportunity for our products; reliance on third parties to develop and commercialize our products; the ability of us and our partners to timely develop, implement and maintain manufacturing, commercialization and marketing capabilities and strategies for our products; intellectual property risks; changes in legal, regulatory, legislative and geopolitical environments in the markets in which we operate and the impact of these changes on our ability to obtain regulatory approval for our products and product candidates; our competitive position; and our ability to raise additional funds and to make payments on our debt obligations as and when necessary.
Any forward-looking statements speak only as of the date on which they are made, and except as may be required under applicable securities laws, Eyenovia does not undertake any obligation to update any forward-looking statements.
Eyenovia Contact:
Eyenovia, Inc.
Norbert Lowe
Vice President, Commercial Operations
admin@eyenovia.com
Eyenovia Investor Contact:
Eric Ribner
LifeSci Advisors, LLC
eric@lifesciadvisors.com
(646) 751-4363
FAQ
What Nasdaq compliance requirements did Eyenovia (EYEN) regain in February 2025?
How did Eyenovia (EYEN) achieve Nasdaq compliance in 2025?
What strategic actions is Eyenovia (EYEN) taking alongside regaining Nasdaq compliance?
What impact does regaining Nasdaq compliance have on Eyenovia (EYEN) shareholders?
